Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03382873 · ClinicalTrials.gov registry record · NA
Augmented Care at Worksite for Diabetes Prevention
A NA study, sponsored by Ohio State University.
- Completed
- Registry status
- NA
- Development phase
- 208
- Enrollment target
NCT03382873: Completed NA study, sponsored by Ohio State University.
NCT03382873 is a NA study that has completed, run by Ohio State University. The registered enrollment target is 208 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03382873, a NA study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 208 participants
- Enrollment target
Study Summary
The purpose of the study was to evaluate the impact of augmented care at the worksite through a lifestyle intervention for diabetes prevention among employees with prediabetes who were slower to respond to a standard diabetes prevention intervention.
Primary Outcome
Change in weight as measured in light clothing and shoes removed
Interventions
- BEHAVIORAL Group Lifestyle Balance (GLB)
- BEHAVIORAL Group Lifestyle Balance Plus (GLB+)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2018-02-08 |
| Est. Completion | 2022-04-15 |
| Phase | NA |
What the finished NCT03382873 record still lists
NCT03382873 is an interventional study that assigns participants to a tested intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 2 interventions - of which Group Lifestyle Balance (GLB) is the first listed.
NCT03382873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03382873 about?
NCT03382873 is a clinical study titled "Augmented Care at Worksite for Diabetes Prevention". The purpose of the study was to evaluate the impact of augmented care at the worksite through a lifestyle intervention for diabetes prevention among employees with prediabetes who were slower to respond to a standard diabetes prevention intervention.
What is the current status of trial NCT03382873?
This trial is currently completed. It is a NA study. The enrollment target is 208 participants. The study started on 2018-02-08. Estimated completion is 2022-04-15.
What interventions are being tested in trial NCT03382873?
The interventions under investigation include: Group Lifestyle Balance (GLB) (BEHAVIORAL), Group Lifestyle Balance Plus (GLB+) (BEHAVIORAL).
Who is sponsoring clinical trial NCT03382873?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03382873's enrollment target sits among peer trials
208 496th of 2000 higher than 1,502 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI